Abstract
Over expression of aldehyde dehydrogenase (ALDH1A1) is one of the vital hallmarks of the self-renewal and differentiational cancer stem cells (CSCs). Till now, no selective ALDH1A1 inhibitor is commercially available in the market. So there is an urgent need to explore some novel molecules which can selectively inhibit ALDH1A1 to combat cancer. Presently, our work deals with the development of QSAR models of some theophylline-based molecules by conventional 2D-QSAR, hologram QSAR (HQSAR), and Bayesian classification modeling. The descriptors identified from these QSAR models give avenues to modulate the structure of theophylline-based compounds to a desirable biological end point. Molecular docking study reveals the selectivity of these molecules towards ALDH1A1 (PDB: 4WP7) and important binding residues (GLY 125, 458; THR 129; TRP 178; TYR 297; PHE 171, 466; VAL 174, 460; MET 175; HIS 293 etc.) for the interaction with the receptors. The current study may help to design novel compounds as selective ALDH1A1 inhibitors.
Keywords: Aldehyde dehydrogenase, theophylline-based inhibitors, QSAR, HQSAR, Bayesian modeling, molecular docking.
Current Drug Discovery Technologies
Title:Insight into the Structural Requirements of Theophylline-Based Aldehyde Dehydrogenase lAl (ALDHlAl) Inhibitors Through Multi-QSAR Modeling and Molecular Docking Approaches
Volume: 13 Issue: 2
Author(s): Sk. Abdul Amin, Nilanjan Adhikari, Shovanlal Gayen and Tarun Jha
Affiliation:
Keywords: Aldehyde dehydrogenase, theophylline-based inhibitors, QSAR, HQSAR, Bayesian modeling, molecular docking.
Abstract: Over expression of aldehyde dehydrogenase (ALDH1A1) is one of the vital hallmarks of the self-renewal and differentiational cancer stem cells (CSCs). Till now, no selective ALDH1A1 inhibitor is commercially available in the market. So there is an urgent need to explore some novel molecules which can selectively inhibit ALDH1A1 to combat cancer. Presently, our work deals with the development of QSAR models of some theophylline-based molecules by conventional 2D-QSAR, hologram QSAR (HQSAR), and Bayesian classification modeling. The descriptors identified from these QSAR models give avenues to modulate the structure of theophylline-based compounds to a desirable biological end point. Molecular docking study reveals the selectivity of these molecules towards ALDH1A1 (PDB: 4WP7) and important binding residues (GLY 125, 458; THR 129; TRP 178; TYR 297; PHE 171, 466; VAL 174, 460; MET 175; HIS 293 etc.) for the interaction with the receptors. The current study may help to design novel compounds as selective ALDH1A1 inhibitors.
Export Options
About this article
Cite this article as:
Abdul Amin Sk., Adhikari Nilanjan, Gayen Shovanlal and Jha Tarun, Insight into the Structural Requirements of Theophylline-Based Aldehyde Dehydrogenase lAl (ALDHlAl) Inhibitors Through Multi-QSAR Modeling and Molecular Docking Approaches, Current Drug Discovery Technologies 2016; 13 (2) . https://dx.doi.org/10.2174/1570163813666160429115628
DOI https://dx.doi.org/10.2174/1570163813666160429115628 |
Print ISSN 1570-1638 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6220 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Gender Differences in the Antioxidant Response to Oxidative Stress in Experimental Brain Tumors
Current Cancer Drug Targets Preface:
Recent Patents on Nanomedicine MicroRNAs: Important Epigenetic Regulators in Osteoarthritis
Current Genomics SAR, QSAR and Docking of Anticancer Flavonoids and Variants: A Review
Current Topics in Medicinal Chemistry Editorial [Hot topic: The Association of Radiotherapy and Chemotherapy (Guest Editor: Maurizio Amichetti)]
Current Drug Therapy Novel Approaches for Modulating dUTPase and Uracil-DNA Glycosylase: Potential Uses for Cancer and Viral Chemotherapy
Drug Design Reviews - Online (Discontinued) A Hybrid Brain Tumor Classification and Detection Mechanism Using Knn and Hmm
Current Medical Imaging New Advances in the Pathogenesis and Progression of Barrett’s Esophagus
Current Molecular Medicine Adaptors in Toll-Like Receptor Signaling and their Potential as Therapeutic Targets
Current Drug Targets A Systems Biology Road Map for the Discovery of Drugs Targeting Cancer Cell Metabolism
Current Pharmaceutical Design Hot Melt Extruded and Injection Moulded Dosage Forms: Recent Research and Patents
Recent Patents on Drug Delivery & Formulation Gap Junctions as Targets for Cancer Chemoprevention and Chemotherapy
Current Drug Targets Merkel Cell Carcinoma – Current State and the Future
Current Cancer Therapy Reviews How to Advise Aspirin Use in Patients Who Need NSAIDs
Current Pharmaceutical Design Cetuximab Immunoliposomes Enhance Delivery of 5-FU to Skin Squamous Carcinoma Cells
Anti-Cancer Agents in Medicinal Chemistry Baicalin-induced Cytotoxicity and Apoptosis in Multidrug-resistant MC3/5FU Mucoepidermoid Carcinoma Cell Line
Letters in Drug Design & Discovery The Development of Epigenetics and Related Inhibitors for Targeted Drug Design in Cancer Therapy
Current Topics in Medicinal Chemistry Rho GTPase Activating Proteins in Cancer Phenotypes
Current Protein & Peptide Science Urokinase Receptor and Integrin Interactions
Current Pharmaceutical Design Antibody-Drug Conjugate Targets
Current Cancer Drug Targets